Stronger Correlation Between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild Lupus

Overview

Journal ISRN Rheumatol

Specialty Rheumatology

Date 2013 Apr 12

PMID 23577265

Citations 5

Authors

Mohammad Reza Hatef

Maryam Sahebari

Zahra Rezaieyazdi

Mohammad Reza Nakhjavani

Mahmoud Mahmoudi

Affiliations

Soon will be listed here.

Abstract

Lupus nephritis (LN) is a major cause of morbidity in patients with systemic lupus erythematosus (SLE). Several cytokines and apoptotic markers such as IL-18 and soluble Fas (sFas) have been assumed to play a role in the pathogenesis of LN. Previous studies confirmed that serum concentrations of sFas and IL-18 are increased in SLE. However, only a few studies have suggested a possible correlation between IL-18 and sFas. This study was planned to continue our previous study on the correlation between those markers to evaluate this correlation in LN. Thirty-two patients with only LN and 46 patients without any major organ involvement participated in this study. SLEDAI score (except for scores related to nephritis) was the same in these two groups. In both groups, patients with any other major organ involvement were excluded. We found a significant rise in the serum concentrations of sFas (P = 0.03) and IL-18 (P = 0.02) in patients with proteinuria compared to those without it. This study showed that the correlation between sFas and IL-18 in LN (P < 0.001, r p = 0.5) is significantly stronger than it is in mild SLE (P < 0.001, r p = 0.4) with similar nonrenal SLEDAI score (P = 0.032, z = 1.85). Between these two serum markers, sFas is the only predictor of proteinuria.

Citing Articles

The Role of Inflammasomes in Glomerulonephritis.

Anton-Pampols P, Diaz-Requena C, Martinez-Valenzuela L, Gomez-Preciado F, Fulladosa X, Vidal-Alabro A Int J Mol Sci. 2022; 23(8).

PMID: 35457026 PMC: 9029880. DOI: 10.3390/ijms23084208.

Genetic and molecular biology of systemic lupus erythematosus among Iranian patients: an overview.

Gachpazan M, Akhlaghipour I, Rahimi H, Saburi E, Mojarrad M, Abbaszadegan M Auto Immun Highlights. 2021; 12(1):2.

PMID: 33516274 PMC: 7847600. DOI: 10.1186/s13317-020-00144-y.

Hypomethylation of interleukin 6 correlates with renal involvement in systemic lupus erythematosus.

Tang C, Li Y, Lin X, Ye J, Li W, He Z Cent Eur J Immunol. 2015; 39(2):203-8.

PMID: 26155125 PMC: 4440029. DOI: 10.5114/ceji.2014.43724.

Soluble fas and the -670 polymorphism of fas in lupus nephritis.

Bollain-Y-Goytia J, Arellano-Rodriguez M, Torres-Del-Muro F, Daza-Benitez L, Munoz-Valle J, Avalos-Diaz E Int J Nephrol. 2014; 2014:780406.

PMID: 25505993 PMC: 4251877. DOI: 10.1155/2014/780406.

The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis?.

Kahlenberg J, Kaplan M Curr Opin Rheumatol. 2014; 26(5):475-81.

PMID: 24992143 PMC: 4153426. DOI: 10.1097/BOR.0000000000000088.

References

Cheng J, Zhou T, Liu C, Shapiro J, BRAUER M, Kiefer M . Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263(5154):1759-62. DOI: 10.1126/science.7510905. View

Alecu M, Coman G, Alecu S . Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med. 2004; 38-39:83-8. View

Tsukinoki T, Sugiyama H, Sunami R, Kobayashi M, Onoda T, Maeshima Y . Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells. Clin Exp Nephrol. 2004; 8(3):196-205. DOI: 10.1007/s10157-004-0301-3. View

El-Masry S, Lotfy M, Nasif W, El-Kady I, Al-Badrawy M . Elevated serum level of interleukin (IL)-18, interferon (IFN)-gamma and soluble Fas in patients with pulmonary complications in tuberculosis. Acta Microbiol Immunol Hung. 2007; 54(1):65-77. DOI: 10.1556/AMicr.54.2007.1.7. View

Telegina E, Reshetnyak T, Moshnikova A, Proussakova O, Zhukova A, Kuznetsova A . A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Immunol Lett. 2008; 122(1):12-7. DOI: 10.1016/j.imlet.2008.10.003. View

Kahlenberg J, Thacker S, Berthier C, Cohen C, Kretzler M, Kaplan M . Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. 2011; 187(11):6143-56. PMC: 3221936. DOI: 10.4049/jimmunol.1101284. View

Gigante A, Gasperini M, Afeltra A, Barbano B, Margiotta D, Cianci R . Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci. 2011; 15(1):15-24. View

Tsai P, Ka S, Chang J, Lai J, Dai M, Jheng H . Antroquinonol differentially modulates T cell activity and reduces interleukin-18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis. Arthritis Rheum. 2011; 64(1):232-42. DOI: 10.1002/art.33328. View

Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M . Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res. 2001; 21(4B):3053-9. View

10.

Fathi N, Hussein M, Hassan H, Mosad E, Galal H, Afifi N . Glomerular expression and elevated serum Bcl-2 and Fas proteins in lupus nephritis: preliminary findings. Clin Exp Immunol. 2006; 146(2):339-43. PMC: 1942057. DOI: 10.1111/j.1365-2249.2006.03219.x. View

11.

Hao J, Ye D, Zhang G, Liu H, Dai H, Huang F . Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch Dermatol Res. 2005; 297(7):329-32. DOI: 10.1007/s00403-005-0616-2. View

12.

Munoz L, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J . Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus. 2008; 17(5):371-5. DOI: 10.1177/0961203308089990. View

13.

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

14.

Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H . Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 1997; 40(6):1126-9. DOI: 10.1002/art.1780400617. View

15.

Kitaura H, Tatamiya M, Nagata N, Fujimura Y, Eguchi T, Yoshida N . IL-18 induces apoptosis of adherent bone marrow cells in TNF-alpha mediated osteoclast formation in synergy with IL-12. Immunol Lett. 2006; 107(1):22-31. DOI: 10.1016/j.imlet.2006.06.005. View

16.

Faust J, Menke J, Kriegsmann J, Kelley V, Mayet W, Galle P . Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum. 2002; 46(11):3083-95. DOI: 10.1002/art.10563. View

17.

Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H . Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol. 1996; 173(2):230-5. DOI: 10.1006/cimm.1996.0272. View

18.

Chen D, Hsieh T, Hsieh C, Lin F, Lan J . Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease. Arthritis Rheum. 2007; 57(8):1530-8. DOI: 10.1002/art.23088. View

19.

Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F . Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus. 2003; 12(1):8-14. DOI: 10.1191/0961203303lu250oa. View

20.

Silvestris F, Cafforio P, Tucci M, Del Prete A, Dammacco F . VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease. Mol Med. 2000; 6(6):509-26. PMC: 1949964. View